CCL5 downregulation was further validated at the mRNA, protein, and serum levels using RT-PCR, qPCR, immunohistochemistry, and ELISA, supporting its potential as a robust biomarker for MetS-induced renal damage. This evidence concerns the gene CCL5 and metabolic syndrome.